Renal Anemia Treatment in the Us- How Payer Policies and Physician Preferences Drive Prescribing and How will the Emerging Oral HIF-PH Inhibitors Influence Payers and Physicians?
Nov 1, 2016, 00:00 AM
10.1016/j.jval.2016.09.1009
https://www.valueinhealthjournal.com/article/S1098-3015(16)32375-0/fulltext
Section Title :
Disease-Specific Studies
Section Order :
947
First Page :
A520
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32375-0&doi=10.1016/j.jval.2016.09.1009